Fig. 5.

(A) Correct vs. incorrect WM time courses are shown across placebo (blue) and ketamine (red) for the precuneus region that exhibited effects of ketamine on WM (defined via the conjunction approach, box shows region coordinates). (B) Relationship between the magnitude of DMN deactivation during WM following ketamine administration and severity of negative symptoms associated with schizophrenia. Subjects showing least DMN suppression during WM were most symptomatic. This effect was specific to WM trials; during control trials under ketamine, this relationship was not evident (r = 0.11).